Journal of Hospice and Palliative Care

  • 제13권1호
  • /
  • Pages.24-31
  • /
  • 2010
  • /
  • 2765-3072(pISSN)
  • /
  • 2765-3080(eISSN)
한국호스피스완화의료학회 (Korean Society for Hospice and Palliative Care)
권호 표지

우리나라 일개 병원 암 환자에서 중심정맥관 합병증에 관한 후향적 조사

Retrospective Analysis for Complications of the Central Venous Catheter in Patients with Cancer at a Single Center in Korea

  • 김은정 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 김현정 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 김한조 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 김경하 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 김세형 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 이상철 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 배상병 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 김찬규 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 이남수 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 이규택 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 박성규 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 원종호 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 박희숙 (순천향대학교 의과대학 혈액종양내과학교실) ;
  • 홍대식 (순천향대학교 의과대학 혈액종양내과학교실)
  • Kim, Eun-Jung (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Kim, Hyun-Jung (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Kim, Han-Jo (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Kim, Kyoung-Ha (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Kim, Se-Hyung (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Lee, Sang-Cheol (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Bae, Sang-Byung (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Kim, Chan-Kyu (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Lee, Nam-Su (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Lee, Kyu-Taek (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Park, Sung-Kyu (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Won, Jong-Ho (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Park, Hee-Sook (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Hong, Dae-Sik (Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine)
  • 발행 : 2010.03.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 암환자에게 있어 중심 정맥관 삽입은 항암치료나 수혈, 비경구 영양공급 목적으로 흔히 시행된다. 중심정맥관 삽입으로 인해 발생하는 합병증으로는 감염, 혈전, 물리적 합병증이 있는데, 이 연구는 합병증의 빈도와 관련 인자들을 규명하기 위해 계획되었다. 방법: 2001년 3월부터 2006년 8월까지 중심 정맥관을 삽입한 고형암과 혈액암 환자를 대상으로 경과기록 분석을 통한 후향적 연구를 시행하였다. 감염, 혈전, 물리적 합병증 각각의 빈도를 조사하였고, 감염과 혈전의 발생에 영향을 미치는 여러 인자들과 그 연관성을 분석하기 위해 교차 분석을 사용하였다. 또한, 삽입관 수명에 영향을 미치는 인자들을 알기 위해 단변량 분석에는 log-rank test를 이용한 Kaplan-Meier 방법과 다변량 분석에는 Cox regression analysis 를 사용하였다. 결과: 310명의 암환자들에게 310개의 중심 정맥관 삽입이 시술되었고, 남자 157명, 여자 153명이었고, 혈액암 환자가 132명, 고형암 환자 178명이었으며, 평균 연령은 52세였다(range: 15~82). 60예(19%)의 환자에서 합병증이 나타났으며, 혈전을 가진 환자에서 감염이 더 빈번하게 일어났고(P=0.003), 암이나 삽입관의 종류, 수혈 및 비경구 영양 시행 여부와 합병증 발생과는 큰 연관성이 없었다. 삽입관의 평균수명은 99일(range: 2~1,330)이었는데 삽입관의 수명은 터널식 삽입관(P=0.000)을 가진 경우에, 그리고 중심정맥관을 통해 수혈을 하지 않은 경우(P=0.030) 더 연장되었다. 결론: 중심 정맥관 삽입의 주요 합병증은 혈전과 감염이었다. 터널식 정맥관은 장기적인 사용에 효과적인 방법이며, 특히 중심정맥관을 통해 수혈을 받지 않는 경우에 그러하다. 중심 정맥관 장기 사용을 위해 혈전과 감염의 예방 및 치료에 대한 연구가 더욱 이루어져야할 것으로 여겨진다.

Purpose: A central venous catheterization (CVC) is frequently used for delivering anti-cancer chemotherapeutic agents, blood products, parenteral nutrition, and other intravenous therapy in patients with cancer. Major complications of CVC use are thrombosis, infection, and mechanical complications. The aim of this study was to evaluate the frequency of CVC complications and related factors. Methods: The records of cancer patients who received a CVC at our university hospital from March 2001 to October 2006 were retrospectively investigated. Chi square test was used to determine whether there was a related factor for thrombosis or infection, and Kaplan-Meier analysis for univariate analysis, or Cox-regression analysis for multivariate analysis was used for catheter life span. Results: Three hundred and ten CVCs (235 nontunneled, 75 tunneled) were inserted in 310 patients (157 males, 153 females). Among them, 104 had hematologic cancers and 206 had solid cancers. The mean age of the patients was 52 years (range, 19~82 years). CVC complications occurred in 60 cases (19%). CVC-related thrombosis occurred frequently in patients with infection (P=0.003), whereas diagnosis, catheter type, transfusion, and TPN history did not affect infection or thrombosis. The mean duration of the catheter was 102 days (range, 2~1,330 days), and the duration was prolonged in patients with tunneled catheters (P=0.000), or without transfusion through CVC (P=0.030). Conclusion: The major complications for long-term use of a CVC were infectionand thrombosis. Tunneled catheter was effective tool for long term use, especially in cases without transfusion through CVC. The studies on the prevention or treatment ofthrombosis and infection are, therefore, warranted by using CVC for an extended period of time.

키워드

참고문헌

  1. Gallieni M, Pittiruti M, Biffi R. Vascular access in oncology patients. CA Cancer J Clin 2008;58(6):323-46. https://doi.org/10.3322/CA.2008.0015
  2. Boersma RS, Jie KS, Verbon A, van Pampus EC, Schouten HC. Thrombotic and infectious complications of central venenous catheters in patients with hematological malignancies. Ann Oncol 2008;19(3):433-42.
  3. Merrer J, De Jonghe B, Golliot F, Lefrant JY, Raffy B, Barre E, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001;286(6):700-7. https://doi.org/10.1001/jama.286.6.700
  4. Vescia S, Baumgärtner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S, et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol 2008;19(1):9-15.
  5. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999;281(3):261-7. https://doi.org/10.1001/jama.281.3.261
  6. Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota DM. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994;331(26):1735-8. https://doi.org/10.1056/NEJM199412293312602
  7. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al. Central venous catheters coated with Minocycline and rifampin for the prevention of catheter related colonization and bloodstream infections: a randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997;127(4):267-74. https://doi.org/10.7326/0003-4819-127-4-199708150-00002
  8. Kim JT, Oh TY. Clinical review of totally implantable venous catheter. Korean J Thorac Cardiovasc Surg 2007;40(10):691-5.
  9. Cho SG, Kim SH, Song HH, Song SH, Lee KH, Chung DY, et al. Radiologic placement of subcutaneous infusion ports in cancer patients: analysis of 45 cases. J Korean Cancer Assoc 2000;32(6): 1115-21.
  10. Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota DM. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994;331(26):1735-8. https://doi.org/10.1056/NEJM199412293312602
  11. Fares LG II, Block PH, Feldman SD. Improved house staff results with subclavian cannulation. Am Surg 1986;52(2):108-11.
  12. Lefrant JY, Cuvillon P, Benezet JF, Dauzat M, Peray P, Saissi G, et al. Pulsed Doppler ultrasonography guidance for catheterization of the subclavian vein: a randomized study. Anesthesiology 1998;88(5):1195-201. https://doi.org/10.1097/00000542-199805000-00009
  13. Bold RJ, Winchester DJ, Madary AR, Gregurich MA, Mansfield PF. Prospective, randomized trial of Doppler-assisted subclavian vein catheterization. Arch Surg 1998;133(10):1089-93. https://doi.org/10.1001/archsurg.133.10.1089
  14. Cortelezzi A, Moia M, Falanga A, Pogliani EM, Agnelli G, Bonizzoni E, et al. CATHEM Study Group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005;129(6):811-7. https://doi.org/10.1111/j.1365-2141.2005.05529.x
  15. van Rooden CJ, Rosendaal FR, Barge RM, van Oostayen JA, van der Meer FJ, Meinders AE, et al. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol 2003;123(3): 507-12. https://doi.org/10.1046/j.1365-2141.2003.04638.x
  16. Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006;24(9):1404-8. https://doi.org/10.1200/JCO.2005.03.5600
  17. Cortelezzia A, Fracchiolla NS, Maisonneuve P, Moia M, Luchesini C, Ranzi ML, et al. Central venous catheter related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures. Leuk Lymphoma 2003;44(9):1495-501. https://doi.org/10.1080/1042819031000103980
  18. Martin C, Viviand X, Saux P, Gouin F. Upper-extremity deep vein thrombosis after central venous catheterization via the axillary vein. Crit Care Med 1999;27(12):2626-9. https://doi.org/10.1097/00003246-199912000-00004
  19. Xiang DZ, Verbeken EK, Van Lommel AT, Stas M, De Wever I. Composition and formation of the sleeve enveloping a central venous catheter. J Vasc Surg 1998;28(2):260-71. https://doi.org/10.1016/S0741-5214(98)70162-4
  20. Monreal M, Lafoz E, Ruiz J, Valls R, Alastrue A. Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 1991;99(2):280-3. https://doi.org/10.1378/chest.99.2.280
  21. Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study. Thromb Haemost 1994;72(4):548-50.
  22. Prandoni P, Polistena P, Bernardi E, Cogo A, Casara D, Verlato F, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157(1):57-62. https://doi.org/10.1001/archinte.157.1.57
  23. Lordick F, Hentrich M, Decker T, Hennig M, Pohlmann H, Hartenstein R, et al. Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheterrelated infections in patients with haemato-oncological diseases: a prospective observational study. Br J Haematol 2003;120(6):1073-8. https://doi.org/10.1046/j.1365-2141.2003.04199.x
  24. Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol 2006;24(28):4575-80. https://doi.org/10.1200/JCO.2005.05.5343
  25. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):401S-28S. https://doi.org/10.1378/chest.126.3_suppl.401S
  26. Karabay O, Yetkin U, Onol H. Upper extremity deep vein thrombosis: clinical and treatment characteristics. J Int Med Res 2004;32(4):429-35. https://doi.org/10.1177/147323000403200413
  27. Frank DA, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD. The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis 2000;10(3):271-5. https://doi.org/10.1023/A:1026503526188
  28. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER. COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial-the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001;12(8):951-5. https://doi.org/10.1016/S1051-0443(07)61575-9
  29. Monturo CA, Dickerson RN, Mullen JL. Efficacy of thrombolytic therapy for occlusion of long-term catheters. JPEN J Parenter Enteral Nutr 1990;14(3):312-4. https://doi.org/10.1177/0148607190014003312
  30. Van Rooden CJ, Monraats PS, Kettenis IM, Rosendaal FR, Huisman MV. Low physician compliance of prescribing anticoagulant prophylaxis in patients with solid tumor or hematological malignancies and central vein catheters. J Thromb Haemost 2003;1(8):1842-3. https://doi.org/10.1046/j.1538-7836.2003.00317.x
  31. Carr KM, Rabinowitz I. Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors. J Clin Oncol 2000;18(21):3665-7. https://doi.org/10.1200/JCO.2000.18.21.3665
  32. Baskin JL, Pui CH, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009;374(9684):159-69. https://doi.org/10.1016/S0140-6736(09)60220-8
  33. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, et al. WARP Collaborative Group, UK. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open label randomised trial. Lancet 2009;373(9663):567-74. https://doi.org/10.1016/S0140-6736(09)60205-1
  34. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, et al. Infectious Diseases Society of America; American College of Critical Care Medicine; Society for Healthcare Epidemiology of America. Guidelines for the management of intravascular catheterrelated infections. Clin Infect Dis 2001;32(9):1249-72. https://doi.org/10.1086/320001
  35. Nouwen JL, Wielenga JJ, van Overhagen H, Lameris JS, Kluytmans JA, Behrendt MD, et al. Hickman catheter-related infections in neutropenic patients: insertion in the operating theater versus insertion in the radiology suite. J Clin Oncol 1999;17(4):1304. https://doi.org/10.1200/JCO.1999.17.4.1304
  36. Trautner BW, Darouiche RO. Catheter-associated infections: pathogenesis affects prevention. Arch Intern Med 2004;164(8):842-50. https://doi.org/10.1001/archinte.164.8.842
  37. Brun-Buisson C, Abrouk F, Legrand P, Huet Y, Larabi S, Rapin M. Diagnosis of central venous catheterrelated sepsis. Critical level of quantitative tip cultures. Arch Intern Med 1987;147(5):873-7. https://doi.org/10.1001/archinte.147.5.873
  38. Catton JA, Dobbins BM, Kite P, Wood JM, Eastwood K, Sugden S, et al. In situ diagnosis of intravascular catheter-related bloodstream infection: a comparison of quantitative culture, differential time to positivity, and endoluminal brushing. Crit Care Med 2005;33(4):787-91. https://doi.org/10.1097/01.CCM.0000157968.98476.F3
  39. Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann Intern Med 2005;142(6):451-66. https://doi.org/10.7326/0003-4819-142-6-200503150-00011
  40. Eggimann P, Hugonnet S, Sax H, Harbarth S, Chevrolet JC, Pittet D. Long-term reduction of vascular access-associated bloodstream infection. Ann Intern Med 2005;142(10):875-6.
  41. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16(2):105-13. https://doi.org/10.1086/647066
  42. Ljungman P, Hagglund H, Bjorkstrand B, Lönnqvist B, Ringden O. Peroperative teicoplanin for prevention of Gram-positive infections in neutropenic patients with indwelling central venous catheters: a randomized, controlled study. Support Care Cancer 1997;5(6):485-8. https://doi.org/10.1007/s005200050117